Who are Olopatadine HCl NS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lastacaft, Xyzal, Elestat, Rupax, Zaditor, Mizollen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/olopatadine-hcl-ns.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Olopatadine HCl NS — Competitive Intelligence Brief

Olopatadine HCl NS (Olopatadine HCl NS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: H1-receptor antagonist / mast cell stabilizer. Area: Allergy / Immunology.

phase 3 H1-receptor antagonist / mast cell stabilizer H1 receptor Allergy / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Olopatadine HCl NS (Olopatadine HCl NS) — Glenmark Specialty S.A.. Olopatadine HCl is a selective H1-receptor antagonist and mast cell stabilizer that reduces allergic inflammation in the nasal cavity.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Olopatadine HCl NS TARGET	Olopatadine HCl NS	Glenmark Specialty S.A.	phase 3	H1-receptor antagonist / mast cell stabilizer	H1 receptor
Lastacaft	ALCAFTADINE	AbbVie	marketed	Histamine-1 Receptor Antagonist [EPC]	Histamine H1 receptor	2010-01-01
Xyzal	LEVOCETIRIZINE	Sanofi	marketed	Histamine-1 Receptor Antagonist	Histamine H1 receptor	2007-01-01
Elestat	EPINASTINE	AbbVie	marketed	Adrenergic Receptor Agonist	Histamine H1 receptor	2003-01-01
Rupax	RUPATADINE	Teikoku Seiyaku	marketed	rupatadine	Histamine H1 receptor	2001-01-01
Zaditor	KETOTIFEN		marketed	Histamine-1 Receptor Inhibitor	Histamine H1 receptor	1999-01-01
Mizollen	MIZOLASTINE	Sanofi	marketed	mizolastine	Histamine H1 receptor	1998-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (H1-receptor antagonist / mast cell stabilizer class)

ALK-Abelló A/S · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Glenmark Specialty S.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Olopatadine HCl NS — Competitive Intelligence Brief. https://druglandscape.com/ci/olopatadine-hcl-ns. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab